Search research articles
Contact Us
Filters
Showing results (21-30 of 187) with videos related to
Page
of 19
Sort By:
Future Oncology (London, England)
|
February 25, 2011
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
Catherine Oakman, Erica Moretti, Libero Santarpia, et al.
Journal of the National Cancer Institute
|
April 5, 2017
RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Miguel Martin, John Boyer, Mary Stuart, et al.
Current Opinion in Obstetrics & Gynecology
|
May 7, 2004
Chemotherapy for metastatic breast cancer
Laura Biganzoli, Alessandro Minisini, Matti Aapro, et al.
Advances in Experimental Medicine and Biology
|
March 19, 2016
Metabolomics in Breast Cancer: Current Status and Perspectives
Christopher D Hart, Leonardo Tenori, Claudio Luchinat, et al.
Nature Reviews. Clinical Oncology
|
December 10, 2009
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart
Clinical Breast Cancer
|
November 12, 2002
Resistance to trastuzumab: a necessary evil or a temporary challenge?
Fatima Cardoso, Martine J Piccart, Virginie Durbecq, et al.
Oncology
|
November 8, 2002
Current status of HER2 testing
Angelo Di Leo, Mitch Dowsett, Bruce Horten, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 28, 2011
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not
Catherine Oakman, Erica Moretti, Giulia Pacini, et al.
Journal of the National Cancer Institute
|
November 7, 2009
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
Catherine Oakman, Erica Moretti, Christos Sotiriou, et al.
Cancer Management and Research
|
December 29, 2010
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
Catherine Oakman, Marta Pestrin, Elena Zafarana, et al.
Page
of 19
Search research articles
Search
Showing results (21-30 of 187) with videos related to
Sort By:
Page
of 19
Future Oncology (London, England)
|
February 25, 2011
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
Catherine Oakman, Erica Moretti, Libero Santarpia, et al.
Journal of the National Cancer Institute
|
April 5, 2017
RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Miguel Martin, John Boyer, Mary Stuart, et al.
Current Opinion in Obstetrics & Gynecology
|
May 7, 2004
Chemotherapy for metastatic breast cancer
Laura Biganzoli, Alessandro Minisini, Matti Aapro, et al.
Advances in Experimental Medicine and Biology
|
March 19, 2016
Metabolomics in Breast Cancer: Current Status and Perspectives
Christopher D Hart, Leonardo Tenori, Claudio Luchinat, et al.
Nature Reviews. Clinical Oncology
|
December 10, 2009
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart
Clinical Breast Cancer
|
November 12, 2002
Resistance to trastuzumab: a necessary evil or a temporary challenge?
Fatima Cardoso, Martine J Piccart, Virginie Durbecq, et al.
Oncology
|
November 8, 2002
Current status of HER2 testing
Angelo Di Leo, Mitch Dowsett, Bruce Horten, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 28, 2011
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not
Catherine Oakman, Erica Moretti, Giulia Pacini, et al.
Journal of the National Cancer Institute
|
November 7, 2009
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
Catherine Oakman, Erica Moretti, Christos Sotiriou, et al.
Cancer Management and Research
|
December 29, 2010
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
Catherine Oakman, Marta Pestrin, Elena Zafarana, et al.
Page
of 19